P

Paragon 28 Inc
NYSE:FNA

Watchlist Manager
Paragon 28 Inc
NYSE:FNA
Watchlist
Price: 13.09 USD Market Closed
Market Cap: 1.1B USD

Paragon 28 Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Paragon 28 Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
P
Paragon 28 Inc
NYSE:FNA
Revenue
$256.2m
CAGR 3-Years
20%
CAGR 5-Years
19%
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Revenue
$20.6B
CAGR 3-Years
4%
CAGR 5-Years
4%
CAGR 10-Years
9%
Boston Scientific Corp
NYSE:BSX
Revenue
$17.6B
CAGR 3-Years
13%
CAGR 5-Years
10%
CAGR 10-Years
9%
Stryker Corp
NYSE:SYK
Revenue
$22.6B
CAGR 3-Years
10%
CAGR 5-Years
9%
CAGR 10-Years
9%
Abbott Laboratories
NYSE:ABT
Revenue
$42.3B
CAGR 3-Years
-2%
CAGR 5-Years
6%
CAGR 10-Years
8%
Intuitive Surgical Inc
NASDAQ:ISRG
Revenue
$8.7B
CAGR 3-Years
14%
CAGR 5-Years
14%
CAGR 10-Years
15%

Paragon 28 Inc
Revenue Breakdown

Breakdown by Geography
Paragon 28 Inc

Total Revenue: 256.2m USD
100%
United States: 212.1m USD
82.8%
Non-Us: 44m USD
17.2%

Breakdown by Segments
Paragon 28 Inc

Total Revenue: 256.2m USD
100%
Represents The Member Information Pertaining ...: 256.2m USD
100%

Paragon 28 Inc
Glance View

Market Cap
1.1B USD
Industry
Health Care

Paragon 28, Inc. engages in operation of an orthopedic foot and ankle company. The company is headquartered in Englewood, Colorado and currently employs 343 full-time employees. The company went IPO on 2021-10-15. The firm develops, distributes and markets medical devices in the foot and ankle segment of the orthopedic implant marketplace. The firm has developed a range of foot and ankle surgical systems and procedural techniques designed to address the primary conditions requiring treatment in the foot and ankle including fracture fixation, hallux valgus bunions, hammertoe, ankle, progressive collapsing foot deformity (PCFD) or flatfoot, Charcot foot, and orthobiologics. The products used in foot and ankle procedures include screws, wires and pins, plates, nails, fixators, staples, joint implants, soft tissue implants, orthobiologics and other implantation instruments and disposables. The firm has developed approximately 6,600 implant, 1,200 instrument, and 900 disposable and other stock keeping units (SKU’s). The company has commercial footprint across United States and International.

FNA Intrinsic Value
12.82 USD
Overvaluation 2%
Intrinsic Value
Price
P

See Also

What is Paragon 28 Inc's Revenue?
Revenue
256.2m USD

Based on the financial report for Dec 31, 2024, Paragon 28 Inc's Revenue amounts to 256.2m USD.

What is Paragon 28 Inc's Revenue growth rate?
Revenue CAGR 5Y
19%

Over the last year, the Revenue growth was 18%. The average annual Revenue growth rates for Paragon 28 Inc have been 20% over the past three years , 19% over the past five years .

Back to Top